Cargando…
Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12
Neuroblastoma immunotherapy using cytokine-modified tumour cells has been tested in clinical trials. However, because of the complex nature of antitumour immune responses, a number of therapies may be required for complete tumour eradication and generation of systemic immunity. We report here the im...
Autores principales: | Siapati, K E, Barker, S, Kinnon, C, Michalski, A, Anderson, R, Brickell, P, Thrasher, A J, Hart, S L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377114/ https://www.ncbi.nlm.nih.gov/pubmed/12771934 http://dx.doi.org/10.1038/sj.bjc.6600928 |
Ejemplares similares
-
Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007) -
β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013) -
Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts
por: Purohit, A, et al.
Publicado: (2003) -
Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts
por: Gerber, S A, et al.
Publicado: (2003) -
Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo
por: Begleiter, A, et al.
Publicado: (2004)